RxDoctor Payments Data

Brooke Porto, PA

Physician Assistant · Williamsville, NYNPI 1861131021

Payments from drug & device makers

$7,949in general payments, 2019–2025

Across 547 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Pfizer$817
  • QOL Medical, LLC$508
  • AbbVie$388
  • Takeda Pharmaceuticals U.S.A., Inc.$293
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$7,67196%
  • Education$2784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,949 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$14,533
Medicare patients
119
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide130$104,209
XifaxanRifaximin18$60,499
RelistorMethylnaltrexone Bromide12$27,435
CreonLipase/Protease/Amylase19$23,355
MotegrityPrucalopride Succinate32$23,294
MovantikNaloxegol Oxalate39$19,853
TrulancePlecanatide15$12,168
Mesalamine28$8,666
Lubiprostone62$6,974
Sucralfate46$6,946
Dexlansoprazole DrDexlansoprazole13$6,268
Omeprazole310$5,835
Pantoprazole Sodium157$4,261
Famotidine176$3,401
Lansoprazole57$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$388$127,564149 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$1,899$100,10245 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$293$23,29432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →